 SAN DIEGO, April 8, 2021 PRNewswire -- Neurocrine Biosciences, Inc. Nasdaq: NBIX today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurologys AAN 73rd Annual Meeting being held virtually from April 1722, 2021. Key highlights include: Analysis from the KINECT 4 Phase III open-label study that demonstrated the effect of INGREZZA valbenazine capsules on the overall severity of abnormal movements in adult patients living with tardive dyskinesia based on item 8 of the abnormal involuntary movement scale AIMS Phase III post-hoc sub-group data analysis that showed long-term use one-year duration of ONGENTYS opicapone capsules in patients with Parkinsons disease with motor fluctuations reduced on time with troublesome dyskinesia and increased on time without troublesome dyskinesia New real-world data from EMPATHY, a retrospective medical chart review, highlight the need to simplify treatment regimens for patients with Parkinsons disease to manage motor fluctuations Results of an online caregiver survey include data on the relationship between genetic variants and disease characteristics in patients with SCN8A developmental epileptic encephalopathy SCN8A-DEE and SCN8A-related epilepsy Data from the Enroll-HD registry, a worldwide observational study, showed that the majority of patients with manifest Huntington disease have chorea, yet the majority of those with chorea were not prescribed medication to treat the condition. 